Insights Into Amicus Therapeutics (FOLD) Q4: Wall Street Projections for Key Metrics

Wall Street analysts forecast that Amicus Therapeutics (FOLD) will report quarterly earnings of $0.10 per share in its upcoming release, pointing to a year-over-year increase of 190.9%. It is anticipated that revenues will amount to $149.53 million, exhibiting an increase of 29.9% compared to the year-ago quarter.The current level reflects a downward revision of 80% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.Given this perspective, it's time to examine the average forecasts of specific Amicus Therapeutics metrics that are routinely monitored and predicted by Wall Street analysts.Analysts predict that the 'Net Product Revenues- Galafold' will reach $140.98 million. The estimate indicates a year-over-year change of +32.3%.The combined assessment of analysts suggests that 'Geographic revenues- Ex-U.S' will likely reach $94.04 million. The estimate points to a change of +30.8% from the year-ago quarter.The consensus among analysts is that 'Geographic revenues- United States' will reach $55.85 million. The estimate suggests a change of +29.4% year over year.View all Key Company Metrics for Amicus Therapeutics here>>>Over the past month, Amicus Therapeutics shares have recorded returns of +3.8% versus the Zacks S&P 500 composite's +4.7% change. Based on its Zacks Rank #3 (Hold), FOLD will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Just Released: Zacks Top 10 Stocks for 2025Hurry – you can still get in early on our 10 top tickers for 2025. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2025. You can still be among the first to see these just-released stocks with enormous potential. See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amicus Therapeutics, Inc. (FOLD): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks